Onconetix, Inc. Investing Cash Flow
Onconetix, Inc. (ONCO) reported Investing Cash Flow of -$28.47 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-03-13
- Onconetix, Inc. net cash provided by (used in) investing activities for the quarter ending 2024-12-31 was -$3.87K, a 100.32% decline year-over-year.
- Onconetix, Inc. net cash provided by (used in) investing activities for the quarter ending 2024-09-30 was -$2.31K, a 101.34% decline year-over-year.
- Onconetix, Inc. net cash provided by (used in) investing activities for the quarter ending 2024-06-30 was -$17.71K.
- Onconetix, Inc. net cash provided by (used in) investing activities for the quarter ending 2024-03-31 was -$4.58K.
- Onconetix, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$28.47K.
- Onconetix, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$8.65M.
- Onconetix, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$32.66K.
- Onconetix, Inc. net cash provided by (used in) investing activities for fiscal 2021 was -$1.92K.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 3 month as first filed | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 6 month as first filed | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 9 month as first filed | Net Cash Provided by (Used in) Investing Activities 12 month | Net Cash Provided by (Used in) Investing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | -$3.87K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$6.19K derived: sum of 2 quarters · filed 2026-03-13 | -$23.89K derived: sum of 3 quarters · filed 2026-03-13 | -$28.47K 10-K · filed 2026-03-13 | ||||
| 2024-09-30 | -$2.31K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$20.02K derived: sum of 2 quarters · filed 2025-11-13 | -$24.60K 10-Q · filed 2025-11-13 | $1.19M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | -$17.71K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$22.28K 10-Q · filed 2025-08-14 | $1.19M derived: sum of 3 quarters · filed 2025-08-14 | $1.37M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | -$4.58K 10-Q · filed 2025-06-12 | $1.21M derived: sum of 2 quarters · filed 2025-06-12 | $1.38M derived: sum of 3 quarters · filed 2025-06-12 | -$8.62M derived: sum of 4 quarters · filed 2025-06-12 | ||||
| 2023-12-31 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-02 | $1.39M derived: sum of 2 quarters · filed 2025-06-02 | -$8.61M derived: sum of 3 quarters · filed 2025-06-02 | -$8.65M 10-K · filed 2025-06-02 | ||||
| 2023-09-30 | $173.01K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-12-10 | -$9.83M derived: sum of 2 quarters · filed 2024-12-10 | -$9.86M 10-Q · filed 2024-12-10 | -$9.87M derived: sum of 4 quarters · filed 2024-12-10 | ||||
| 2023-06-30 | -$10.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-29 | -$10.04M 10-Q · filed 2024-08-29 | -$10.04M derived: sum of 3 quarters · filed 2024-08-29 | -$10.05M derived: sum of 4 quarters · filed 2024-08-29 | ||||
| 2023-03-31 | -$36.27K 10-Q · filed 2024-05-20 | -$1.82K 10-Q · filed 2023-05-12 | -$37.45K derived: sum of 2 quarters · filed 2024-05-20 | -$51.76K derived: sum of 3 quarters · filed 2024-05-20 | -$63.74K derived: sum of 4 quarters · filed 2024-05-20 | |||
| 2022-12-31 | -$1.18K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-11 | -$15.49K derived: sum of 2 quarters · filed 2024-04-11 | -$27.47K derived: sum of 3 quarters · filed 2024-04-11 | -$32.66K 10-K · filed 2024-04-11 | -$9.34K 10-K · filed 2023-03-09 | |||
| 2022-09-30 | -$14.31K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-17 | -$26.29K derived: sum of 2 quarters · filed 2023-11-17 | -$31.49K 10-Q · filed 2023-11-17 | -$9.34K 10-Q · filed 2022-11-14 | ||||
| 2022-06-30 | -$11.98K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-10-20 | -$17.18K 10-Q · filed 2023-10-20 | -$9.34K 10-Q · filed 2022-08-15 | |||||
| 2022-03-31 | -$5.20K 10-Q · filed 2023-05-12 | |||||||
| 2021-12-31 | -$1.92K 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |